Application of different doses of urokinase in the treatment of thrombosis of arteriovenous internal fistula

Abstract

Objective \nTo investigate the efficacy and safety of different doses of urokinase in the treatment of arteriovenous fistula thrombosis. \n \n \nMethods \nFrom January 2011 to September 2018, 118 patients underwent maintenance hemodialysis and autologous arteriovenous thrombosis in the department of nephrology of our hospital who were divided into three groups: group A (100 000 units of urokinase ), group B (500 000 units of urokinase ) and group C (1 million units of urokinase ) according to the dosage of urokinase thrombolysis. We compared the success rate of thrombolysis between the three groups and the incidence of thrombolysis complications between group B and group C. \n \n \nResults \nThe success rate of thrombolysis in group C was significantly better than that in group A and B (P 0.05). \n \n \nConclusions \nOne million units of urokinase can significantly improve the success rate of thrombolysis of arteriovenous fistula, while the incidence of complications is not significantly different from 500 000 units, extending the service life of arteriovenous fistula in maintenance hemodialysis patients, without increasing the risk of bleeding complications, and effectively improving the quality of dialysis. \n \n \nKey words: \nUrokinase-Type Plasminogen Activator;\xa0Arteriovenous Anastomosis;\xa0Thrombosis